Skip to main content

Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.

Publication ,  Journal Article
Pop-Busui, R; Lu, J; Brooks, MM; Albert, S; Althouse, AD; Escobedo, J; Green, J; Palumbo, P; Perkins, BA; Whitehouse, F; Jones, TLZ ...
Published in: Diabetes Care
October 2013

OBJECTIVE: The Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial demonstrated similar long-term clinical effectiveness of insulin-sensitizing (IS) versus insulin-providing (IP) treatments for type 2 diabetes on cardiovascular outcomes in a cohort with documented coronary artery disease. We evaluated the effects of randomized glycemic control strategy (IS vs. IP) on the prevalence and incidence of diabetic peripheral neuropathy (DPN). RESEARCH DESIGN AND METHODS: DPN (defined as Michigan Neuropathy Screening Instrument [MNSI] clinical examination score>2) was assessed at baseline and yearly for 4 years. DPN prevalence and incidence were compared by intention-to-treat modeling by logistic generalized estimating equation models for prevalence and Kaplan-Meier estimates and Cox regression models for incidence rates. RESULTS: Results are reported for 2,159 BARI 2D participants (70% males) with valid baseline and at least one follow-up MNSI score (mean age 62±9 years, mean HbA1c 7.7±1.6%, diabetes duration 10±9 years). There were no differences in the prevalence of DPN between the IS and the IP groups throughout the 4 years of follow-up. In 1,075 BARI 2D participants with no DPN at baseline, the 4-year cumulative incidence rate of DPN was significantly lower in the IS (66%) than in the IP (72%) strategy group (P=0.02), which remained significant after adjusting for the in-trial HbA1c (P=0.04). In subgroup analyses, IS strategy had a greater benefit in men (hazard ratio 0.75 [99% CI 0.58-0.99], P<0.01). CONCLUSIONS: Among patients with type 2 diabetes followed for up to 4 years during BARI 2D, a glycemic control therapy with IS significantly reduced the incidence of DPN compared with IP therapy and may add further benefit for men.

Duke Scholars

Published In

Diabetes Care

DOI

EISSN

1935-5548

Publication Date

October 2013

Volume

36

Issue

10

Start / End Page

3208 / 3215

Location

United States

Related Subject Headings

  • Peripheral Nervous System Diseases
  • Middle Aged
  • Male
  • Hypoglycemic Agents
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Diabetic Neuropathies
  • Diabetes Mellitus, Type 2
  • Blood Glucose
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pop-Busui, R., Lu, J., Brooks, M. M., Albert, S., Althouse, A. D., Escobedo, J., … BARI 2D Study Group. (2013). Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care, 36(10), 3208–3215. https://doi.org/10.2337/dc13-0012
Pop-Busui, Rodica, Jiang Lu, Maria Mori Brooks, Stewart Albert, Andrew D. Althouse, Jorge Escobedo, Jenifer Green, et al. “Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.Diabetes Care 36, no. 10 (October 2013): 3208–15. https://doi.org/10.2337/dc13-0012.
Pop-Busui, Rodica, et al. “Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort.Diabetes Care, vol. 36, no. 10, Oct. 2013, pp. 3208–15. Pubmed, doi:10.2337/dc13-0012.
Pop-Busui R, Lu J, Brooks MM, Albert S, Althouse AD, Escobedo J, Green J, Palumbo P, Perkins BA, Whitehouse F, Jones TLZ, BARI 2D Study Group. Impact of glycemic control strategies on the progression of diabetic peripheral neuropathy in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Cohort. Diabetes Care. 2013 Oct;36(10):3208–3215.

Published In

Diabetes Care

DOI

EISSN

1935-5548

Publication Date

October 2013

Volume

36

Issue

10

Start / End Page

3208 / 3215

Location

United States

Related Subject Headings

  • Peripheral Nervous System Diseases
  • Middle Aged
  • Male
  • Hypoglycemic Agents
  • Humans
  • Female
  • Endocrinology & Metabolism
  • Diabetic Neuropathies
  • Diabetes Mellitus, Type 2
  • Blood Glucose